Benjamin Pickard, MD
Internal Medicine · Lafayette, LANPI 1790351831
Payments from drug & device makers
What this record shows
This record is dominated by grants: $9,091 of the $9,911 with a category attached, or 91.7%. Abbott accounts for 94.9% of it on its own, with 8 other manufacturers making up the rest. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $762.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Edwards Lifesciences$221
- Scpharmaceuticals Inc.$155
- Merck$29
- E.r. Squibb & Sons, L.L.C.$23
- Johnson & Johnson$21
- plus $57 from 3 others
What the payments were for
- Grants$9,09192%
- Food & beverage$6757%
- Education$1451%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 4 | $9,405 |
| Edwards Lifesciences | 1 | $221 |
| Scpharmaceuticals Inc. | 2 | $155 |
| Merck | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Amgen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,911 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $23,536 |
| JardianceEmpagliflozin | 14 | $11,427 |
| Atorvastatin Calcium | 64 | $980 |
| Amlodipine Besylate | 39 | $436 |
| Lisinopril | 27 | $370 |
| Metformin Hcl | 17 | $347 |
| Carvedilol | 19 | $304 |
| Omeprazole | 13 | $282 |
| Losartan Potassium | 26 | $217 |
| Gabapentin | 14 | $207 |
| Metoprolol Tartrate | 16 | $140 |
| Pantoprazole Sodium | 16 | $54 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Lafayette
- Bryan LebeanLafayette$53K
- Nethuja SalagundlaLafayette$32K
- Hector RoblesLafayette$19K
- Brad BroussardLafayette$17K
- Juan Perez-RuizLafayette$12K
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Bruce SamuelsCovington$200K
- Amanda FontenotMarrero$142K
- John SchwabBaton Rouge$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.